Fungi concerns spark nationwide recall of Zicam® and Orajel™ products
(WJW) – According to the U.S. Food and Drug Administration, Church & Dwight Co., Inc. is voluntarily recalling some Zicam® and Orajel™ products because fungi could be present in the items' cotton swab components.
The recalled products include all lots within expiry of Zicam® Cold Remedy Nasal Swabs, Zicam® Nasal AllClear Swabs, and Orajel™ Baby Teething Swabs to the consumer level.
Consumers are advised to 'immediately' stop using the recalled products.
Major grocery chain slashing prices for the summer
'Swabs found to contain microbial contamination can potentially present a significant risk to the health and safety of consumers including serious and life-threatening blood infections in users whose nasal mucosa may be compromised due to inflammation and mechanical injuries,' reads the recall alert. 'The risk is highest (potentially severe or life-threatening) among children and individuals with compromised immune systems or other underlying medical conditions.'
The FDA said, so far, no serious adverse events associated with the affected product have been reported. The recalled products were distributed nationwide in the United States and in Puerto Rico, said the FDA.
Brain-eating amoeba: How are people infected?
Here's the specific details to check for:
Zicam® Cold Remedy Nasal Swabs, with UPC 732216301205, all lots: A zinc-free, homeopathic cold remedy swab designed to shorten the duration of the common cold.
Zicam® Nasal AllClear Swabs, with UPC 732216301656, all lots: A nasal cleansing swab product (discontinued in December 2024).
Orajel™ Baby Teething Swabs, with UPC 310310400002, all lots: Pre-moistened swabs designed to soothe teething discomfort in infants and toddlers.
You can view images of the recalled products in the slideshow below:
'This recall is limited exclusively to Zicam and Orajel swab products. All other Zicam and Orajel products, including Zicam RapidMelts, are not affected by this recall,' states the FDA on its website.
Consumers can CLICK HERE or call (800) 981-4710 for refund details.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Nano-Cap PolyPid's Lead Drug Candidate Cuts Surgical Infection Risk by 38% In Phase 3 Trial
PolyPid Ltd. (NASDAQ:PYPD) on Monday announced topline results from its pivotal SHIELD II Phase 3 trial of D-PLEX100 to prevent surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. The SHIELD II trial is designed to assess the efficacy and safety of D-PLEX100 administered concomitantly with the standard of care (SoC), which includes prophylactic systemic antibiotics, compared to the SoC alone arm in the prevention of post-abdominal-surgery incisional infection in patients undergoing abdominal colorectal surgeries with large incisions. The trial's primary endpoint is measured by the proportion of subjects with a surgical site infection or mortality for any reason within 30 days post-surgery. FDA Pushes Pause On Axsome Fibromyalgia Drug, New Trial Required Patient safety will be monitored for an additional 30 days. The trial will enroll patients in centers in the United States, Europe, and Israel. D-PLEX100, PolyPid's lead product candidate, is designed to provide local, prolonged, and controlled antibacterial activity directly at the surgical site to prevent SSIs. Following the administration of D-PLEX100 into the surgical site, the PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients, enabling a prolonged and continuous release of the broad-spectrum antibiotic doxycycline, resulting in a high local concentration of the drug for 30 days for the prevention of SSIs, with additional potential to prevent SSIs caused by antibiotic-resistant bacteria at the surgical site. The trial met the primary efficacy endpoint, with a significantly lower proportion of primary endpoint events among patients who received D-PLEX100 plus SoC (n=405; 10.9%), compared to SoC alone (n=393; 18.1%), representing a 38% reduction (p<0.005). SHIELD II included three key secondary endpoints: The first key secondary endpoint was met, with a 58% reduction in deep and superficial SSI rates among patients who received D-PLEX100 plus SoC (3.8%) compared to those who received SoC alone (9.5%) (p<0.005). The second key secondary endpoint showed statistical significance in favor of D-PLEX100 plus SoC over SoC alone (p<0.005). The third key secondary endpoint was met with a 62% reduction of patients with an ASEPSIS1 score >20 in the D-PLEX100 plus SoC arm compared to the SoC alone arm (p<0.05). The ASEPSIS score is a clinical tool used to assess surgical wound infections objectively. The independent Data Safety Monitoring Board raised no safety concerns in SHIELD II. The company expects to submit a New Drug Application to the U.S. Food and Drug Administration in early 2026, with a Marketing Authorization Application in the E.U. to follow shortly thereafter. Price Action: PYPD stock is trading higher by 12% to $3.66 at last check Monday. Read Next:Photo by ittawit21 via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Nano-Cap PolyPid's Lead Drug Candidate Cuts Surgical Infection Risk by 38% In Phase 3 Trial originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.
Scientific American
an hour ago
- Scientific American
Science-Backed Ways to Stay Healthy During Salmonella Outbreak in Eggs
3 min read To prevent salmonella food poisoning, refrigerate your eggs, cook them well, never eat them raw, and clean, clean, clean By edited by Dean Visser At least 79 people have been sickened by a salmonella outbreak linked to organic and cage-free eggs, distributed under various brand names across seven U.S. states. The eggs were processed by the August Egg Company in Hilmar, Calif., according to the Food and Drug Administration (FDA). On June 6, after FDA tests discovered the bacteria, the company issued a wide recall. The recall is just the latest in a string of callbacks linked to salmonella contamination. On June 7, TGD Cuts of Jessup, Md., recalled cucumber and salsa products, and on June 4 the FDA urged consumers to follow a recall that began in May of tomatoes packaged and shipped by various companies. What is salmonella, how can it make you sick, and how can you minimize your chances of getting it? Here are some basics. On supporting science journalism If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today. What Is Salmonella and How Does It Spread? Salmonella is a bacterium that thrives in the intestinal tract of certain animals, including chickens and cows—and humans. It is shed through feces. Like many foodborne pathogens, salmonella is often spread by improper cleaning or handling of raw food—including meat, eggs, seafood, vegetables, fruits and rice—at farms or factories. It is often associated with chicken and eggs, although past outbreaks have also been linked to peanut butter, raw pork and beef, cucumbers and even raw flour in cookie dough. When compromised products are shipped, stores and consumers may be unaware of the contamination until enough people start becoming sick and investigators trace the source back to specific food lots. The U.S. Centers for Disease Control and Prevention (CDC) estimates that 48 million Americans get sick from food each year. What Are the Symptoms of Salmonella Food Poisoning? You may begin to feel sick anywhere from eight to 72 hours after you are exposed. As the bacteria multiply, they can cause stomach cramps, diarrhea, vomiting and fever. Children under age five often account for a large percentage of cases in a Salmonella outbreak, and elderly people or those with weakened immune systems are at greater risk. In rare cases people develop joint pain or eye irritation. How Is It Treated? Infections often clear within three or four days, but if diarrhea lasts for more than two days, or body temperature rises above 102 degrees Fahrenheit, health officials urge you to see a doctor. Complications such as diarrhea can cause dehydration, so drink plenty of fluids. How Can I Minimize My Chances of Getting Salmonella? Contaminated food is the chief source, so never eat raw foods that can carry the bacteria. Refrigerate eggs or other susceptible foods at 40 degrees Fahrenheit or less. When preparing meals, use separate cutting boards and knives for suspect foods, and thoroughly wash them—as well as kitchen surfaces and your hands after prep. Microwave dishwashing sponges on high. Cook food to at least 160 degrees Fahrenheit (71 degrees Celsius). Should I Stop Kissing my own Chickens? Birds, hedgehogs, turtles, guinea pigs and even pet bearded dragons can carry Salmonella and make you sick through direct contact, according to a 2024 Scientific American story. The craze among homeowners that expanded during Covid to raise chickens in the backyard is also a culprit. Salmonella bacteria can linger on an animal's skin, so regardless of how cute you think your chickens are, try to not snuggle them or kiss them! Which evidently is a thing.
Yahoo
2 hours ago
- Yahoo
Phillips Medisize Launches TheraVolt Medical Connectors to Support Next-Gen Device Integration, Connectivity and Performance
Designed to address increasing demand for advanced medical connectors in growing specialties such as electrophysiology Enhanced cross-platform compatibility helps simplify device integration, increase longevity of capital equipment, reduce customization development time and lower costs The first of several Phillips Medisize–branded medical connectors planned to launch over the next 18–24 months, TheraVolt™ provides device engineers enhanced functionality, offering solutions to handle both signals and high voltage lines These tailored offerings for medical applications leverage 80+ years of global leadership in interconnect solutions from Molex, combined with Phillips Medisize's 60+ years of medical experience HUDSON, Wis., June 09, 2025--(BUSINESS WIRE)--Phillips Medisize, a Molex company and a leader in the design, engineering and manufacturing of medtech, pharmaceutical drug delivery and in vitro diagnostic devices, announces the launch of TheraVolt™ Medical Connectors. As the first medical connectors launched under the Phillips Medisize brand, TheraVolt is engineered to optimize device integration, functionality, reliability and performance. TheraVolt provides device engineers enhanced functionality, offering solutions to handle both signals and high voltage lines. Emerging trends in electrophysiology (EP), most notably the rapid adoption of pulsed field ablation (PFA) technology, are driving increased demand for advanced medical connectors that support higher pin count densities and compact design. With enhanced cross-platform compatibility, TheraVolt Medical Connectors help simplify medical device integration, increase longevity of capital equipment, reduce customization development time and lower costs. This can enable more efficient solutions and greater flexibility for medical device companies developing PFA treatment for patients living with atrial fibrillation. "With the launch of TheraVolt, the first of several Phillips Medisize–branded connectors, we are excited to bring deeper collaboration and innovation to complement our exceptional contract design and manufacturing services and proven Molex connectivity solutions to our medtech customers," said Pete Soupir, vice president, MedTech segment at Phillips Medisize. "TheraVolt Medical Connectors empower our medical device customers to develop next-gen EP devices with enhanced integration, connectivity and performance. Their high pin count and high voltage clearance is particularly valuable in medical devices used in electrophysiology treatments, with multiple therapy options, complex functions and expanded data collection." These tailored offerings for medical applications leverage 80+ years of global leadership in interconnect solutions from Molex, combined with more than 60 years of medical experience from Phillips Medisize. TheraVolt Medical Connectors support next-generation medical device integration and performance through: High Pin Count and Voltage Clearance: Enables the integration of more functionalities, allowing medical device engineers to design multi-therapy medical devices with expanded capabilities, advanced functions and increased data collection. Design Flexibility and Customization: Available off-the-shelf with the flexibility to be tailored to meet diverse application demands, with customizable configurations for specific pin counts and precise electrical requirements. Sterilization Compatibility: Engineered to withstand multiple autoclave cycles, maintaining integrity and performance even under repeated exposure to harsh sterilization processes. Safety and Reliability: Designed to support compliance with IEC and IPC requirements, helping to promote dependable operation in medical applications. Additional Phillips Medisize Medical Connectors are in development and will be delivered over the next 18–24 months. Learn more about TheraVolt Medical Connectors at and About Phillips Medisize Phillips Medisize, a Molex company, collaborates with leading medical technology, pharmaceutical and in vitro diagnostic companies to design, engineer and manufacture lifesaving innovations. A contract development and manufacturing organization (CDMO), Phillips Medisize leverages its 60 years of expertise and globally renowned capabilities to collaborate with customers to deliver products and solutions that annually help millions of patients, healthcare professionals and individuals live healthier, more productive lives. For more information, visit About Molex Molex is a global electronics leader committed to making the world a better, more-connected place. With a presence in more than 38 countries, Molex enables transformative technology innovation in the consumer device, aerospace and defense, data center, cloud, telecommunications, transportation, industrial automation, and healthcare industries. Through trusted customer and industry relationships, unrivaled engineering expertise, and product quality and reliability, Molex realizes the infinite potential of Creating Connections for Life. For more information, visit View source version on Contacts Media Contact: Merryman CommunicationsHelen Winklerhelen@
